<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="9" family="Arial,Italic" color="#000000"/>
	<fontspec id="font1" size="9" family="Arial" color="#000000"/>
	<fontspec id="font2" size="9" family="Arial,Bold" color="#000000"/>
	<fontspec id="font3" size="7" family="Arial,Italic" color="#000000"/>
	<fontspec id="font4" size="10" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font5" size="10" family="Giovanni,Bold" color="#000000"/>
	<fontspec id="font6" size="9" family="GillSans,BoldItalic" color="#000000"/>
	<fontspec id="font7" size="7" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font8" size="10" family="Giovanni-BookItalic,Italic" color="#000000"/>
	<fontspec id="font9" size="11" family="GillSans,Bold" color="#000000"/>
<text top="41" left="55" width="125" height="10" font="font0" id="p1_t1" reading_order_no="0" segment_no="0" tag_type="title"><i>Behavioral and Brain Functions</i></text>
<text top="41" left="180" width="28" height="10" font="font1" id="p1_t2" reading_order_no="1" segment_no="0" tag_type="title"> 2005, </text>
<text top="41" left="207" width="5" height="10" font="font2" id="p1_t3" reading_order_no="2" segment_no="0" tag_type="title"><b>1</b></text>
<text top="41" left="213" width="12" height="10" font="font1" id="p1_t4" reading_order_no="3" segment_no="0" tag_type="title">:19</text>
<text top="41" left="318" width="236" height="10" font="font1" id="p1_t5" reading_order_no="4" segment_no="1" tag_type="text">http://www.behavioralandbrainfunctions.com/content/1/1/19</text>
<text top="756" left="508" width="46" height="10" font="font1" id="p1_t6" reading_order_no="130" segment_no="11" tag_type="text">Page 3 of 9</text>
<text top="769" left="432" width="122" height="8" font="font3" id="p1_t7" reading_order_no="131" segment_no="12" tag_type="text"><i>(page number not for citation purposes)</i></text>
<text top="87" left="55" width="241" height="9" font="font4" id="p1_t8" reading_order_no="5" segment_no="2" tag_type="text">Center. The CAT monitors the inpatient and outpatient</text>
<text top="98" left="55" width="241" height="9" font="font4" id="p1_t9" reading_order_no="6" segment_no="2" tag_type="text">hospital census daily and conducts preliminary screening</text>
<text top="110" left="55" width="241" height="9" font="font4" id="p1_t10" reading_order_no="7" segment_no="2" tag_type="text">and recruitment functions. Inclusion criteria for screening</text>
<text top="122" left="55" width="241" height="9" font="font4" id="p1_t11" reading_order_no="8" segment_no="2" tag_type="text">for this study included a clinical diagnosis of a psychotic</text>
<text top="134" left="55" width="241" height="9" font="font4" id="p1_t12" reading_order_no="9" segment_no="2" tag_type="text">disorder, no active substance abuse, and ability to provide</text>
<text top="145" left="55" width="241" height="9" font="font4" id="p1_t13" reading_order_no="10" segment_no="2" tag_type="text">informed consent. After obtaining written informed con-</text>
<text top="157" left="55" width="241" height="9" font="font4" id="p1_t14" reading_order_no="11" segment_no="2" tag_type="text">sent, each subject was assessed with the Structured Clini-</text>
<text top="169" left="55" width="241" height="9" font="font4" id="p1_t15" reading_order_no="12" segment_no="2" tag_type="text">cal Interview for DSM-IV Axis I Disorders (SCID: version</text>
<text top="181" left="55" width="241" height="9" font="font4" id="p1_t16" reading_order_no="13" segment_no="2" tag_type="text">2.0, 8/98), administered by trained raters. Standardized</text>
<text top="192" left="55" width="241" height="9" font="font4" id="p1_t17" reading_order_no="14" segment_no="2" tag_type="text">diagnostic assessments were supplemented with clinical</text>
<text top="204" left="55" width="241" height="9" font="font4" id="p1_t18" reading_order_no="15" segment_no="2" tag_type="text">information obtained by review of medical records and</text>
<text top="216" left="55" width="241" height="9" font="font4" id="p1_t19" reading_order_no="16" segment_no="2" tag_type="text">interviews with family informants when possible, and all</text>
<text top="228" left="55" width="241" height="9" font="font4" id="p1_t20" reading_order_no="17" segment_no="2" tag_type="text">diagnostic information was compiled into a narrative case</text>
<text top="239" left="55" width="241" height="9" font="font4" id="p1_t21" reading_order_no="18" segment_no="2" tag_type="text">summary. Information on the onset and course of Axis I</text>
<text top="251" left="55" width="241" height="9" font="font4" id="p1_t22" reading_order_no="19" segment_no="2" tag_type="text">illness, presence of Axis II pathology, presence of Axis III</text>
<text top="263" left="55" width="241" height="9" font="font4" id="p1_t23" reading_order_no="20" segment_no="2" tag_type="text">diagnoses, and a brief description of the subject's psycho-</text>
<text top="275" left="55" width="241" height="9" font="font4" id="p1_t24" reading_order_no="21" segment_no="2" tag_type="text">social and occupational functioning during the course of</text>
<text top="286" left="55" width="241" height="9" font="font4" id="p1_t25" reading_order_no="22" segment_no="2" tag_type="text">illness was presented to a consensus diagnostic committee</text>
<text top="298" left="55" width="241" height="9" font="font4" id="p1_t26" reading_order_no="23" segment_no="2" tag_type="text">consisting of a minimum of three senior faculty with</text>
<text top="310" left="55" width="241" height="9" font="font4" id="p1_t27" reading_order_no="24" segment_no="2" tag_type="text">DSM-IV diagnostic experience, as well as other faculty and</text>
<text top="322" left="55" width="241" height="9" font="font4" id="p1_t28" reading_order_no="25" segment_no="2" tag_type="text">trainees with SCID experience. All available information</text>
<text top="333" left="55" width="241" height="9" font="font4" id="p1_t29" reading_order_no="26" segment_no="2" tag_type="text">was used to arrive at a consensus DSM-IV diagnosis.</text>
<text top="345" left="55" width="78" height="9" font="font5" id="p1_t30" reading_order_no="27" segment_no="2" tag_type="text"><b>Healthy controls </b></text>
<text top="345" left="134" width="162" height="9" font="font4" id="p1_t31" reading_order_no="28" segment_no="2" tag_type="text">were ascertained and recruited by the</text>
<text top="357" left="55" width="241" height="9" font="font4" id="p1_t32" reading_order_no="29" segment_no="2" tag_type="text">Zucker Hillside Hospital Normal Control Program.</text>
<text top="369" left="55" width="241" height="9" font="font4" id="p1_t33" reading_order_no="30" segment_no="2" tag_type="text">Potential participants were recruited via local newspaper</text>
<text top="380" left="55" width="241" height="9" font="font4" id="p1_t34" reading_order_no="31" segment_no="2" tag_type="text">advertisements, flyers and community internet resources</text>
<text top="392" left="55" width="241" height="9" font="font4" id="p1_t35" reading_order_no="32" segment_no="2" tag_type="text">and underwent initial telephone screening to assess eligi-</text>
<text top="404" left="55" width="241" height="9" font="font4" id="p1_t36" reading_order_no="33" segment_no="2" tag_type="text">bility criteria. Subjects meeting eligibility criteria were</text>
<text top="416" left="55" width="241" height="9" font="font4" id="p1_t37" reading_order_no="34" segment_no="2" tag_type="text">administered the SCID â€“ NP to rule out the presence of an</text>
<text top="427" left="55" width="241" height="9" font="font4" id="p1_t38" reading_order_no="35" segment_no="2" tag_type="text">Axis I psychiatric disorder, urine toxicology screen for</text>
<text top="439" left="55" width="241" height="9" font="font4" id="p1_t39" reading_order_no="36" segment_no="2" tag_type="text">drugs of and a family history of psychiatric disorder</text>
<text top="451" left="55" width="241" height="9" font="font4" id="p1_t40" reading_order_no="37" segment_no="2" tag_type="text">assessment. Exclusion criteria included current or past:</text>
<text top="463" left="55" width="241" height="9" font="font4" id="p1_t41" reading_order_no="38" segment_no="2" tag_type="text">Axis I psychiatric disorder, psychotropic drug treatment,</text>
<text top="474" left="55" width="241" height="9" font="font4" id="p1_t42" reading_order_no="39" segment_no="2" tag_type="text">substance abuse, first-degree family member with an Axis</text>
<text top="486" left="55" width="241" height="9" font="font4" id="p1_t43" reading_order_no="40" segment_no="2" tag_type="text">I psychiatric disorder, or inability to provide written</text>
<text top="498" left="55" width="241" height="9" font="font4" id="p1_t44" reading_order_no="41" segment_no="2" tag_type="text">informed consent. A subset of the control cohort was col-</text>
<text top="510" left="55" width="241" height="9" font="font4" id="p1_t45" reading_order_no="42" segment_no="2" tag_type="text">lected through the Massachusetts General Hospital Clini-</text>
<text top="521" left="55" width="241" height="9" font="font4" id="p1_t46" reading_order_no="43" segment_no="2" tag_type="text">cal Research Program in conjunction with the Harvard-</text>
<text top="533" left="55" width="241" height="9" font="font4" id="p1_t47" reading_order_no="44" segment_no="2" tag_type="text">Partners Center for Genetics and Genomics in Boston,</text>
<text top="545" left="55" width="241" height="9" font="font4" id="p1_t48" reading_order_no="45" segment_no="2" tag_type="text">MA. This subset comprised disease free subjects over the</text>
<text top="557" left="55" width="241" height="9" font="font4" id="p1_t49" reading_order_no="46" segment_no="2" tag_type="text">age of 18. For the purposes of the study, "disease" was</text>
<text top="568" left="55" width="241" height="9" font="font4" id="p1_t50" reading_order_no="47" segment_no="2" tag_type="text">defined as current or past diagnoses made by a medical</text>
<text top="580" left="55" width="241" height="9" font="font4" id="p1_t51" reading_order_no="48" segment_no="2" tag_type="text">care provider that required medication or other forms of</text>
<text top="592" left="55" width="241" height="9" font="font4" id="p1_t52" reading_order_no="49" segment_no="2" tag_type="text">treatment/therapy. With the exception of orthopedic pro-</text>
<text top="604" left="55" width="241" height="9" font="font4" id="p1_t53" reading_order_no="50" segment_no="2" tag_type="text">cedures, appendectomy, or those that were trauma</text>
<text top="615" left="55" width="241" height="9" font="font4" id="p1_t54" reading_order_no="51" segment_no="2" tag_type="text">related, surgery was considered an exclusionary criterion.</text>
<text top="627" left="55" width="241" height="9" font="font4" id="p1_t55" reading_order_no="52" segment_no="2" tag_type="text">Subjects who took prescription medications or regularly</text>
<text top="639" left="55" width="241" height="9" font="font4" id="p1_t56" reading_order_no="53" segment_no="2" tag_type="text">used over the counter medications were also excluded.</text>
<text top="651" left="55" width="241" height="9" font="font4" id="p1_t57" reading_order_no="54" segment_no="2" tag_type="text">These subjects completed a structured family and medical</text>
<text top="662" left="55" width="241" height="9" font="font4" id="p1_t58" reading_order_no="55" segment_no="2" tag_type="text">questionnaire that detailed current and past history of</text>
<text top="674" left="55" width="241" height="9" font="font4" id="p1_t59" reading_order_no="56" segment_no="2" tag_type="text">psychiatric illness and pharmacological or psychothera-</text>
<text top="686" left="55" width="241" height="9" font="font4" id="p1_t60" reading_order_no="57" segment_no="2" tag_type="text">peutic psychiatric treatment. All responses to the self-</text>
<text top="698" left="55" width="241" height="9" font="font4" id="p1_t61" reading_order_no="58" segment_no="2" tag_type="text">report form were confirmed by clinical interview by phy-</text>
<text top="709" left="55" width="241" height="9" font="font4" id="p1_t62" reading_order_no="59" segment_no="2" tag_type="text">sicians. Physical exams were completed at the study visit.</text>
<text top="87" left="313" width="241" height="9" font="font4" id="p1_t63" reading_order_no="60" segment_no="3" tag_type="text">This study was approved by the Institutional Review</text>
<text top="98" left="313" width="180" height="9" font="font4" id="p1_t64" reading_order_no="61" segment_no="3" tag_type="text">Board at NSLIJHS and Partners Healthcare.</text>
<text top="122" left="313" width="48" height="9" font="font6" id="p1_t65" reading_order_no="62" segment_no="4" tag_type="title"><i><b>Genotyping</b></i></text>
<text top="134" left="313" width="241" height="9" font="font4" id="p1_t66" reading_order_no="63" segment_no="5" tag_type="text">All samples were genotyped using the ABI PRISM 7900HT</text>
<text top="145" left="313" width="241" height="9" font="font4" id="p1_t67" reading_order_no="64" segment_no="5" tag_type="text">Sequence Detection System (Applied Biosystems, Foster</text>
<text top="157" left="313" width="179" height="9" font="font4" id="p1_t68" reading_order_no="65" segment_no="5" tag_type="text">City, CA). The 5' nuclease assay (TaqMan</text>
<text top="157" left="492" width="3" height="6" font="font7" id="p1_t69" reading_order_no="66" segment_no="5" tag_type="text">Â®</text>
<text top="157" left="496" width="58" height="9" font="font4" id="p1_t70" reading_order_no="67" segment_no="5" tag_type="text">) was used to</text>
<text top="169" left="313" width="241" height="9" font="font4" id="p1_t71" reading_order_no="68" segment_no="5" tag_type="text">distinguish the two alleles of a gene. PCR amplification</text>
<text top="181" left="313" width="218" height="9" font="font4" id="p1_t72" reading_order_no="69" segment_no="5" tag_type="text">was carried out on 5â€“20 ng DNA using 1 Ã— TaqMan</text>
<text top="180" left="531" width="5" height="6" font="font7" id="p1_t73" reading_order_no="70" segment_no="5" tag_type="text">Â® </text>
<text top="181" left="537" width="17" height="9" font="font4" id="p1_t74" reading_order_no="71" segment_no="5" tag_type="text">uni-</text>
<text top="192" left="313" width="241" height="9" font="font4" id="p1_t75" reading_order_no="72" segment_no="5" tag_type="text">versal PCR master mix (No Amp-erase UNG), 900 nM for-</text>
<text top="204" left="313" width="241" height="9" font="font4" id="p1_t76" reading_order_no="73" segment_no="5" tag_type="text">ward and reverse primers, 200 nM of the FAM labeled</text>
<text top="216" left="313" width="241" height="9" font="font4" id="p1_t77" reading_order_no="74" segment_no="5" tag_type="text">probe and 200 nM of the VIC labeled probe in a 5 ul reac-</text>
<text top="228" left="313" width="241" height="9" font="font4" id="p1_t78" reading_order_no="75" segment_no="5" tag_type="text">tion volume. Amplification conditions on an AB 9700</text>
<text top="239" left="313" width="241" height="9" font="font4" id="p1_t79" reading_order_no="76" segment_no="5" tag_type="text">dual plate thermal cycle (Applied Biosystems, Foster City,</text>
<text top="251" left="313" width="241" height="9" font="font4" id="p1_t80" reading_order_no="77" segment_no="5" tag_type="text">CA) were as follows: 1 cycle of 95Â°C for 10 min, followed</text>
<text top="263" left="313" width="241" height="9" font="font4" id="p1_t81" reading_order_no="78" segment_no="5" tag_type="text">by 50 cycles of 92Â°C for 15 s and 58Â°C for 1 min. Taq-</text>
<text top="275" left="313" width="19" height="9" font="font4" id="p1_t82" reading_order_no="79" segment_no="5" tag_type="text">Man</text>
<text top="274" left="332" width="5" height="6" font="font7" id="p1_t83" reading_order_no="80" segment_no="5" tag_type="text">Â® </text>
<text top="275" left="337" width="217" height="9" font="font4" id="p1_t84" reading_order_no="81" segment_no="5" tag_type="text">primers and probes were designed using the Primer</text>
<text top="286" left="313" width="31" height="9" font="font4" id="p1_t85" reading_order_no="82" segment_no="5" tag_type="text">Express</text>
<text top="286" left="344" width="5" height="6" font="font7" id="p1_t86" reading_order_no="83" segment_no="5" tag_type="text">Â® </text>
<text top="286" left="349" width="205" height="9" font="font4" id="p1_t87" reading_order_no="84" segment_no="5" tag_type="text">Oligo Design software v2.0 (ABI PRISM) or using</text>
<text top="298" left="313" width="139" height="9" font="font4" id="p1_t88" reading_order_no="85" segment_no="5" tag_type="text">the ABI Assays-By-Design service.</text>
<text top="322" left="313" width="79" height="9" font="font6" id="p1_t89" reading_order_no="86" segment_no="6" tag_type="title"><i><b>Statistical Analyses</b></i></text>
<text top="333" left="313" width="241" height="9" font="font4" id="p1_t90" reading_order_no="87" segment_no="7" tag_type="text">Tests of Hardy-Weinberg equilibrium (HWE) were per-</text>
<text top="345" left="313" width="241" height="9" font="font4" id="p1_t91" reading_order_no="88" segment_no="7" tag_type="text">formed at each SNP locus [<a href="">48]</a>. Application of the test for</text>
<text top="357" left="313" width="241" height="9" font="font4" id="p1_t92" reading_order_no="89" segment_no="7" tag_type="text">HWE was restricted to the control samples from each eth-</text>
<text top="369" left="313" width="241" height="9" font="font4" id="p1_t93" reading_order_no="90" segment_no="7" tag_type="text">nic group as a means of identification of genotyping prob-</text>
<text top="380" left="313" width="25" height="9" font="font4" id="p1_t94" reading_order_no="91" segment_no="7" tag_type="text">lems. </text>
<text top="380" left="339" width="88" height="9" font="font8" id="p1_t95" reading_order_no="92" segment_no="7" tag_type="text"><i>Single SNP analyses: </i></text>
<text top="380" left="427" width="127" height="9" font="font4" id="p1_t96" reading_order_no="93" segment_no="7" tag_type="text">Statistical inference for single</text>
<text top="392" left="313" width="241" height="9" font="font4" id="p1_t97" reading_order_no="94" segment_no="7" tag_type="text">SNP associations was based on Chi-square test statistics.</text>
<text top="404" left="313" width="241" height="9" font="font4" id="p1_t98" reading_order_no="95" segment_no="7" tag_type="text">For each SNP an allelic association test and the Cochran-</text>
<text top="416" left="313" width="241" height="9" font="font4" id="p1_t99" reading_order_no="96" segment_no="7" tag_type="text">Armitage trend test (test for additive allelic effects) were</text>
<text top="427" left="313" width="75" height="9" font="font4" id="p1_t100" reading_order_no="97" segment_no="7" tag_type="text">performed [<a href="">49]</a>. </text>
<text top="427" left="388" width="84" height="9" font="font8" id="p1_t101" reading_order_no="98" segment_no="7" tag_type="text"><i>Haplotype analyses: </i></text>
<text top="427" left="472" width="82" height="9" font="font4" id="p1_t102" reading_order_no="99" segment_no="7" tag_type="text">Haplotype associa-</text>
<text top="439" left="313" width="241" height="9" font="font4" id="p1_t103" reading_order_no="100" segment_no="7" tag_type="text">tions were explored using score tests that account for link-</text>
<text top="451" left="313" width="241" height="9" font="font4" id="p1_t104" reading_order_no="101" segment_no="7" tag_type="text">age phase ambiguity [<a href="">50]</a>. The score tests, derived from</text>
<text top="463" left="313" width="241" height="9" font="font4" id="p1_t105" reading_order_no="102" segment_no="7" tag_type="text">generalized linear models, are used for global tests of asso-</text>
<text top="474" left="313" width="241" height="9" font="font4" id="p1_t106" reading_order_no="103" segment_no="7" tag_type="text">ciation, as well as haplotype-specific tests. In addition, a</text>
<text top="486" left="313" width="241" height="9" font="font4" id="p1_t107" reading_order_no="104" segment_no="7" tag_type="text">permutation algorithm was applied in the testing frame-</text>
<text top="498" left="313" width="241" height="9" font="font4" id="p1_t108" reading_order_no="105" segment_no="7" tag_type="text">work to find the maximum of the haplotype-specific score</text>
<text top="510" left="313" width="178" height="9" font="font4" id="p1_t109" reading_order_no="106" segment_no="7" tag_type="text">statistics and its associated p-value. The </text>
<text top="510" left="491" width="43" height="9" font="font8" id="p1_t110" reading_order_no="107" segment_no="7" tag_type="text"><i>haplo.stats </i></text>
<text top="510" left="536" width="18" height="9" font="font4" id="p1_t111" reading_order_no="108" segment_no="7" tag_type="text">pro-</text>
<text top="521" left="313" width="180" height="9" font="font4" id="p1_t112" reading_order_no="109" segment_no="7" tag_type="text">gram implements the methods of Schaid </text>
<text top="521" left="493" width="18" height="9" font="font8" id="p1_t113" reading_order_no="110" segment_no="7" tag_type="text"><i>et al</i></text>
<text top="521" left="511" width="43" height="9" font="font4" id="p1_t114" reading_order_no="111" segment_no="7" tag_type="text"><a href="">. [50</a>] and</text>
<text top="533" left="313" width="241" height="9" font="font4" id="p1_t115" reading_order_no="112" segment_no="7" tag_type="text">was used for these analyses. Haplotypes were imputed</text>
<text top="545" left="313" width="241" height="9" font="font4" id="p1_t116" reading_order_no="113" segment_no="7" tag_type="text">and frequencies estimated using the EM-algorithm-based</text>
<text top="557" left="313" width="89" height="9" font="font4" id="p1_t117" reading_order_no="114" segment_no="7" tag_type="text">estimation facility in </text>
<text top="557" left="402" width="41" height="9" font="font8" id="p1_t118" reading_order_no="115" segment_no="7" tag_type="text"><i>haplo.stats</i></text>
<text top="557" left="443" width="3" height="9" font="font4" id="p1_t119" reading_order_no="116" segment_no="7" tag_type="text">.</text>
<text top="580" left="313" width="36" height="10" font="font9" id="p1_t120" reading_order_no="117" segment_no="8" tag_type="title"><b>Results</b></text>
<text top="592" left="313" width="83" height="9" font="font6" id="p1_t121" reading_order_no="118" segment_no="9" tag_type="title"><i><b>Single SNP analyses</b></i></text>
<text top="604" left="313" width="241" height="9" font="font4" id="p1_t122" reading_order_no="119" segment_no="10" tag_type="text">We tested four COMT SNPs (-278 A/G, rs737865, Val108/</text>
<text top="615" left="313" width="241" height="9" font="font4" id="p1_t123" reading_order_no="120" segment_no="10" tag_type="text">158Met and rs165599) for association with diagnosis in</text>
<text top="627" left="313" width="241" height="9" font="font4" id="p1_t124" reading_order_no="121" segment_no="10" tag_type="text">our sample of 394 US-Caucasian cases and 467 controls.</text>
<text top="639" left="313" width="241" height="9" font="font4" id="p1_t125" reading_order_no="122" segment_no="10" tag_type="text">All SNPs were in HWE (data not shown). The results of the</text>
<text top="651" left="313" width="241" height="9" font="font4" id="p1_t126" reading_order_no="123" segment_no="10" tag_type="text">single SNP analysis are presented in Table <a href="">1.</a> Three of the</text>
<text top="662" left="313" width="241" height="9" font="font4" id="p1_t127" reading_order_no="124" segment_no="10" tag_type="text">four SNPs were significantly associated with our broad</text>
<text top="674" left="313" width="241" height="9" font="font4" id="p1_t128" reading_order_no="125" segment_no="10" tag_type="text">"all affecteds" diagnosis: -278 A/G (p = 0.004; OR = 1.34),</text>
<text top="686" left="313" width="241" height="9" font="font4" id="p1_t129" reading_order_no="126" segment_no="10" tag_type="text">Val108/158Met (p = 0.05; OR = 1.21) and rs165599 (p =</text>
<text top="698" left="313" width="241" height="9" font="font4" id="p1_t130" reading_order_no="127" segment_no="10" tag_type="text">0.035; OR = 1.25). When the cases were restricted to</text>
<text top="709" left="313" width="241" height="9" font="font4" id="p1_t131" reading_order_no="128" segment_no="10" tag_type="text">patients with schizophrenia or schizoaffective disorder (n</text>
<text top="721" left="313" width="241" height="9" font="font4" id="p1_t132" reading_order_no="129" segment_no="10" tag_type="text">= 258), only the promoter polymorphism (-278 A/G)</text>
</page>
</pdf2xml>
